Evidence map›Paper›PMID 32430586›Full record

ArticleDer Pathologe2020

[Molecular tumor diagnostics-current methods, examples of application and future].

B Sobottka, A Weber

Abstract read
PubMed Publisher
In one paragraph

Article in Der Pathologe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

B SobottkaInstitut für Pathologie und Molekularpathologie, Universitätsspital Zürich, Universität Zürich, Schmelzbergstraße 12, 8091, Zürich, Schweiz.
A WeberInstitut für Pathologie und Molekularpathologie, Universitätsspital Zürich, Universität Zürich, Schmelzbergstraße 12, 8091, Zürich, Schweiz. achim.weber@usz.ch.
University Hospital of Zurich · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular tumor diagnostics is rapidly evolving, driven by technological advances in high-throughput sequencing and bioinformatics, and paralleled by the emergence of novel therapeutic approaches, not least in the field of immune oncology. Molecular stratification of common tumor entities such as colorectal carcinoma and the discovery of paradigmatic molecular changes such as NTRK fusions illustrate how molecular pathological investigations can be performed under diagnostic or predictive conditions and can also provide prognostic information. Promising recent developments include "liquid biopsy" and tumor agnostic strategies. A functioning interdisciplinary cooperation between oncology, bioinformatics and molecular pathology is prerequisite for modern oncological diagnostics based on the current state-of-the-art knowledge and decisive for optimal care of oncological patients.

Indexed as

Biomarkers, TumorMolecular Diagnostic TechniquesHigh-Throughput Nucleotide SequencingHumansMedical OncologyPathology, MolecularBiomarkers, TumorBioinformaticsHigh-throughput sequencingPathology, molecularPersonalized medicinePredictive molecular testing

Identifiers

PMID32430586
OpenAlexW3028026952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.